{"nctId":"NCT01614470","briefTitle":"Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation","startDateStruct":{"date":"2012-07"},"conditions":["Cystic Fibrosis"],"count":39,"armGroups":[{"label":"Part 1: Ivacaftor First, Then Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor","Drug: Placebo"]},{"label":"Part 1: Placebo First, Then Ivacaftor","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor","Drug: Placebo"]},{"label":"Part 2: Ivacaftor","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor"]}],"interventions":[{"name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female with confirmed diagnosis of CF\n* At least 1 allele of the following CFTR gating mutations: G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D\n* Percent predicted forced expiratory volume in 1 second (FEV1) greater than or equal to (\\>=) 40 percent (%) predicted normal for age, sex, and height\n* 6 years of age or older\n* Minimum weight of 15 kilogram (kg) at screening\n* Females of childbearing potential must not be pregnant\n* Willing to comply with contraception requirements\n\nExclusion Criteria:\n\n* G551D-CFTR mutation on at least 1 allele\n* History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject\n* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug\n* History of solid organ or hematological transplantation\n* History of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug\n* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening\n* Use of inhaled hypertonic saline treatment\n* Use of any inhibitors or inducers of cytochrome (CYP) P450 3A\n* Evidence of cataract or lens opacity at screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3659","spread":"20.33450"},{"groupId":"OG001","value":"79.3361","spread":"20.83991"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1308","spread":"9.94676"},{"groupId":"OG001","value":"-5.8738","spread":"7.23722"}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in Body Mass Index (BMI) at Week 8","description":"BMI was defined as weight in kilogram (kg) divided by height in meters\\^2 (m\\^2). Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.241","spread":"5.1880"},{"groupId":"OG001","value":"22.527","spread":"4.9956"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.748","spread":"0.5793"},{"groupId":"OG001","value":"0.043","spread":"0.6980"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Body Mass Index (BMI) at 24 Weeks of Treatment (Week 36 Visit)","description":"BMI was defined as weight in kg divided by height in m\\^2. Change in BMI over 24 weeks of ivacaftor treatment (from Week 12 \\[Part 1: Treatment Period 2\\] through Week 36 \\[Part 2\\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.222","spread":"6.2919"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.263","spread":"0.7588"}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in Sweat Chloride Through Week 8","description":"Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.37","spread":"18.099"},{"groupId":"OG001","value":"94.23","spread":"20.581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.82","spread":"24.890"},{"groupId":"OG001","value":"-5.63","spread":"9.833"}]}]}]},{"type":"PRIMARY","title":"Part 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment (Week 36 Visit)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Absolute change in percent predicted FEV1 over 24 weeks of ivacaftor treatment (from Week 12 \\[Part 1: Treatment Period 2\\] through Week 36 \\[Part 2\\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2, as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8375","spread":"19.36754"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5307","spread":"10.18174"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Sweat Chloride Through 24 Weeks of Treatment (Week 36 Visit)","description":"Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\\>=) 15 microliter was required for determination of sweat chloride. Change in sweat chloride over 24 weeks of ivacaftor treatment (from Week 12 \\[Part 1: Treatment Period 2\\] through Week 36 \\[Part 2\\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.03","spread":"11.468"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.24","spread":"32.566"}]}]}]},{"type":"SECONDARY","title":"Part 1: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8","description":"The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.61","spread":"17.409"},{"groupId":"OG001","value":"74.55","spread":"20.616"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.31","spread":"16.891"},{"groupId":"OG001","value":"-2.33","spread":"20.648"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through 24 Weeks of Treatment (Week 36 Visit)","description":"The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Change in CFQ-R respiratory domain score over 24 weeks of ivacaftor treatment (from Week 12 \\[Part 1: Treatment Period 2\\] through Week 36 \\[Part 2\\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.30","spread":"19.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.42","spread":"13.604"}]}]}]},{"type":"SECONDARY","title":"Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":38},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Sputum increased","Abdominal pain"]}}}